Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.

@article{Bai2016EvaluationOT,
  title={Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.},
  author={Stephen A. Bai and Qinfang Xiang and Andrew L. Finn},
  journal={Clinical therapeutics},
  year={2016},
  volume={38 2},
  pages={
          358-69
        }
}
PURPOSE Buprenorphine, a partial μ-receptor agonist, is approved for the management of moderate to severe pain, but it has low oral bioavailability. Two open-label studies were performed to determine the pharmacokinetic profile of buprenorphine from buccal film formulations of buprenorphine. METHODS Both studies enrolled healthy volunteers, aged 18 to 55 years, who received concurrent oral naltrexone to reduce adverse events (AEs); subjects with a history or evidence of substance abuse or… Expand
The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine
TLDR
The results suggest that this novel sublingual buprenorphine wafer may provide enhanced clinical utility in the management of both acute and chronic pain. Expand
Pharmacokinetics of Sublingual Buprenorphine Tablets Following Single and Multiple Doses in Chinese Participants With and Without Opioid Use Disorder
TLDR
The present data suggest that buprenorphine/naloxone pharmacokinetic profiles in Chinese participants are consistent, overall, with those in Western populations, supporting no differences in dosing. Expand
Long-term safety and analgesic efficacy of buprenorphine buccal film in patients with moderate-to-severe chronic pain requiring around-the-clock opioids
TLDR
In appropriate patients, buprenorphine buccal film demonstrated tolerability and efficacy in the long-term management of chronic pain. Expand
Voriconazole greatly increases the exposure to oral buprenorphine
TLDR
Voriconazole greatly increases exposure to oral buprenorphine, mainly by inhibiting intestinal and liver CYP3A4, and effect on some transporters may explain elevated norbuprenorphines concentrations. Expand
Converting from Transdermal to Buccal Formulations of Buprenorphine: A Pharmacokinetic Meta-Model Simulation in Healthy Volunteers
TLDR
Computer modeling and simulations using a meta-model built from data extracted from publications suggest that rapid and straightforward conversion from transdermal to buccal buprenorphine is feasible. Expand
Intravenous Buprenorphine Micro-dosing Induction in a Patient on Methadone Treatment: A Case Report
TLDR
This case demonstrates a successful and well tolerated buprenorphine induction without interruption of methadone treatment or precipitation of significant opioid withdrawal. Expand
Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option
TLDR
Although originally designed as an analgesic, buprenorphine has mainly been used for opioid maintenance therapy and only now is increasingly recognized as an effective analgesic with an improved therapeutic index relative to certain potent opioids. Expand
Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates
TLDR
The applicability of scaling adult PBPK models to pediatrics for the prediction of individual plasma profiles is demonstrated and could be helpful to further investigate buprenorphine pharmacokinetics in various populations, particularly pediatric subgroups. Expand
A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration
TLDR
The validated PBPK models developed were robust in predicting the multicompartment disposition of BUP over a dosing range of 0.3-32 mg and will be used in future studies to predict BUP plasma and brain concentrations based on the varying demographic, physiological and pathological characteristics of patients. Expand
Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics
TLDR
This article reviews the PK/PD of NOWS pharmacotherapies with a focus on the implication of physiological development and maturation and suggests the model-informed approach holds promise to aid more rational use of medications in the treatment of NOWs. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 38 REFERENCES
Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
TLDR
The serum concentration achieved by 16 mg of tablet buprenorphine is higher than that of the 8 mg solution, although differences between physiologic, subjective and objective opioid effects were not noted, and clinicians should consider using less than 16 mg to achieve bioequivalence to the 8mg solution. Expand
Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block.
TLDR
Sublingual buprenorphine, up to 40 times the 400 microg analgesic dose, was well tolerated in these opioid naïve subjects, as administration of naltrexone 50-150 mg was sufficient to attenuate anticipated adverse effects in this population of subjects. Expand
Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.
TLDR
Investigation of buprenorphine pharmacokinetics by different routes of administration at dosages approximating those used in opioid-dependence studies found that the terminal elimination half-life of norbuprenorphines was longer than bupenorphine and the mean peak plasma concentrations were less than 1 ng/mL. Expand
Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence.
TLDR
Probuphine implants offer significant promise for enhancing delivery of effective opioid substitution treatment while minimizing risk for abuse of medication, according to an initial, open-label evaluation in heroin-dependent volunteers. Expand
Acute administration of buprenorphine in humans: partial agonist and blockade effects.
TLDR
There is a ceiling on the effects of buprenorphine in humans that may reduce its abuse liability and increase its safety, and indicate that opioid blockade occurs after acute administration of bu p.o.m. or methadone. Expand
Gender differences in pharmacokinetics of maintenance dosed buprenorphine.
TLDR
Gender-related differences exist in the pharmacokinetics of buprenorphine; Differences in body composition appear to have a major impact; differences in CYPA-dependent metabolism may also contribute. Expand
Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study.
TLDR
Results of a pivotal Phase 3 study that assesses a new treatment for the management of chronic low back pain: a transdermal patch containing the opioid buprenorphine (BTDS), found to be efficacious and generally well tolerated. Expand
Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile
TLDR
Buprenorphine exhibits a pronounced antihyperalgesic effect that might indicate potential advantages in the treatment of neuropathic pain, and its favorable safety profile and proven efficacy in severe pain and favorable tolerability mean that it can be considered a safe and effective option for treating chronic cancer and noncancer pain. Expand
Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
TLDR
The fact that this retrospective analysis conducted in identical cohorts showed lower calculated equipotent oral morphine doses in the buprenorphine TD groups compared with the fentanyl TD groups calls into question the proposed 1:75 ratio for conversion of bupreliminary data from prospective randomized clinical trials are needed. Expand
Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects.
TLDR
Tramadol was found to have limited detoxification efficacy in moderate to severe opioid withdrawal and substantial risk of seizures as compared to buprenorphine. Expand
...
1
2
3
4
...